Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy

BACKGROUND: Health‐related quality of life (HRQOL) in patients with chronic‐phase chronic myeloid leukemia (CML) is important because of the requirement for long‐term treatment. This study assessed HRQOL in bosutinib‐treated patients with Philadelphia chromosome–positive CML and resistance or intole...

Descripción completa

Detalles Bibliográficos
Autores principales: Kantarjian, Hagop M., Mamolo, Carla M., Gambacorti‐Passerini, Carlo, Cortes, Jorge E., Brümmendorf, Tim H., Su, Yun, Reisman, Arlene L., Shapiro, Mark, Lipton, Jeff H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813200/
https://www.ncbi.nlm.nih.gov/pubmed/29072772
http://dx.doi.org/10.1002/cncr.31082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813200/
https://www.ncbi.nlm.nih.gov/pubmed/29072772
http://dx.doi.org/10.1002/cncr.31082

Ejemplares similares